HomeInsightsStock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Unichem Laboratories Ltd Stock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Unichem Laboratories Ltd Stock Comparison

Last Updated on: May 03, 2025

Key Highlights

  • The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2852 as of 02 May 15:30.
  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 226.4 on March 2020 to 55.8 on March 2024 . This represents a CAGR of -24.43% over 5 yearsThe P/E Ratio of Unichem Laboratories Ltd changed from 63.4 on March 2021 to 0 on March 2024 . This represents a CAGR of -100.00% over 4 years.
  • The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 21095 crore on March 2020 to ₹ 32917 crore on March 2024 . This represents a CAGR of 9.31% over 5 yearsThe Market Cap of Unichem Laboratories Ltd changed from ₹ 1065 crore on March 2020 to ₹ 3439 crore on March 2024 . This represents a CAGR of 26.41% over 5 years.
  • The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '24 is ₹ 984.49 crore as compare to the Sep '24 revenue of ₹ 1050 crore. This represent the decline of -6.24% The revenue of Unichem Laboratories Ltd for the Dec '24 is ₹ 546.71 crore as compare to the Sep '24 revenue of ₹ 516.05 crore. This represent the growth of 5.94%.
  • The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '24 is ₹ 326.99 crore as compare to the Sep '24 ebitda of ₹ 360.94 crore. This represent the decline of -9.41% The ebitda of Unichem Laboratories Ltd for the Dec '24 is ₹ 99.14 crore as compare to the Sep '24 ebitda of ₹ 64.18 crore. This represent the growth of 54.47%.
  • The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 132.25 crore to ₹ 229.88 crore over 7 quarters. This represents a CAGR of 37.15% The net profit of Unichem Laboratories Ltd changed from ₹ -0.67 crore to ₹ 57.85 crore over 7 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 615.76 % on March 2020 to 92.72 % on March 2024 . This represents a CAGR of -31.52% over 5 yearsThe Dividend Payout of Unichem Laboratories Ltd changed from -50 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. The Company's portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease.
  • Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases.

About Unichem Laboratories Ltd

  • Unichem Laboratories Limited is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients.
  • The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division.
  • The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh. The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia).
  • The Baddi plant was approved by UK MHRA and MCC (South Africa).
  • The company received ISO 9001:2000 for all their plants and corporate office.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GlaxoSmithKline Pharmaceuticals to conduct board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

19 Apr 2025 09:56

News

Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmala...

Read more

06 Feb 2025 12:00

News

GlaxoSmithKline Pharmaceuticals revises board meeting date

GlaxoSmithKline Pharmaceuticals has revised the meeting of the Board of Directors which wa...

Read more

21 Jan 2025 11:16

News

GlaxoSmithKline Pharmaceuticals declare Quarterly Result

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

15 Jan 2025 15:27

News

GSK Pharma gains as Q2 PAT rises 15% YoY to Rs 249 cr

Profit before exceptional item and tax was at Rs 338.70 crore in the September 2024 quarte...

Read more

30 Oct 2024 10:39

News

Board of GlaxoSmithKline Pharmaceuticals recommends Special Interim Dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

29 Oct 2024 16:10

Unichem Laboratories Ltd News Hub

News

Unichem Laboratories receives upgrade in credit ratings from ICRA

Unichem Laboratories announced that t ICRA, the credit rating agency has upgraded the rati...

Read more

18 Feb 2025 19:58

News

Unichem Laboratories schedules board meeting

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 6 Feb...

Read more

14 Jan 2025 14:54

News

Unichem Laboratories to discuss results

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 13 No...

Read more

25 Oct 2024 16:49

News

Unichem Laboratories to hold board meeting

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 30 Se...

Read more

23 Sep 2024 10:11

News

Board of Unichem Laboratories to consider proposal for consolidation of generic formulations biz in US

The Board of Unichem Laboratories will meet on 30 September 2024 to consider and approve i...

Read more

23 Sep 2024 09:45

News

Unichem Labs gains on proposal to consolidate USA generics formulations business under one entity

In an exchange filing made before market hours today, the company said that its board will...

Read more

23 Sep 2024 09:26

SWOT Analysis Of Unichem Laboratories Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Unichem Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Unichem Laboratories Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Unichem Laboratories Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 48,322 Cr while Market cap of Unichem Laboratories Ltd is 4,144 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Unichem Laboratories Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Unichem Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Unichem Laboratories Ltd?

As of May 3, 2025, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2852.45. On the other hand, Unichem Laboratories Ltd stock price is INR ₹588.6.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Unichem Laboratories Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Unichem Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions